share_log

House votes to decriminalize marijuana

House votes to decriminalize marijuana

眾議院投票決定大麻合法化
Dow Jones ·  2022/04/04 04:22  · 市場

By Camille Furst

卡米爾·弗斯特著

The U.S. House of Representatives passed a bill Friday to decriminalize marijuana, yet Senate passage is unlikely.

美國眾議院星期五通過了一項大麻合法化的法案,但參議院不太可能通過。

The Marijuana Opportunity Reinvestment and Expungement Act, or the MORE Act, would remove marijuana from the list of scheduled substances in the Controlled Substances Act. Cannabis is currently a Schedule I drug, on the same level as heroin, and deemed to have no accepted medical use and a high potential for abuse. It is the second push for such legislation.

大麻機會再投資和消除法案,或更多法案,將從受控物質法案的受管制物質清單中刪除大麻。大麻目前屬於附表一藥物,與海洛因處於同一水平,被認為沒有被接受的醫療用途和很大的濫用潛力。這是推動此類立法的第二次努力。

The bill also would prevent anyone who possesses, distributes or manufactures marijuana from facing criminal penalties. Thirty-seven states have already adopted laws legalizing cannabis for medical use, while 15 allow it for recreational use, according to the bill.

該法案還將防止任何擁有、分銷或製造大麻的人面臨刑事處罰。根據該法案,37個州已經通過了法律,將大麻用於醫療用途合法化,而15個州允許將其用於娛樂用途。

The MORE Act passed in the House largely along party lines in a 220-204 vote, with all but two Democrats voting for it. It received the support of three Republicans: Rep. Matt Gaetz and Rep. Brian Mast of Florida, and Rep. Tom McClintock of California.

More法案在眾議院以220票對204票在很大程度上符合黨派界限,除兩名民主黨人外,所有人都投了贊成票。它得到了三名共和黨人的支持:佛羅裏達州眾議員馬特·蓋茨(Matt Gaetz)和眾議員布萊恩·馬斯特(Brian Mast)以及加利福尼亞州眾議員湯姆·麥克林托克(Tom McClintock)。

The bill is now headed to the Senate, where its path will likely be more difficult. The legislation will require 60 votes to pass, and the Senate is split 50-50 between Democrats and Republicans.

該法案現在正被送往參議院,在那裏它的道路可能會更加艱難。這項立法需要60票才能通過,參議院民主黨人和共和黨人各佔一半。

The move to decriminalize cannabis has faced opposition from some Republicans and some moderate Democrats.

大麻合法化的舉措遭到了一些共和黨人和一些温和派民主黨人的反對。

While more than two in three Americans support legalizing marijuana, according to a 2021 Gallup poll, there are significant differences in views based on political affiliation. The poll found that 81% of Republicans described the problem of drugs in the U.S. as extremely or very serious, compared with 54% of Democrats.

根據2021年蓋洛普的一項民意調查,儘管超過三分之二的美國人支持大麻合法化,但基於政治派別的觀點存在顯著差異。民調發現,81%的共和黨人將美國的毒品問題描述為極端或非常嚴重,相比之下,54%的民主黨人認為毒品問題非常嚴重。

Steven Hawkins of the U.S. Cannabis Council, an organization advocating for the legalization of marijuana, said he thinks the bill is unlikely to pass in the Senate.

美國大麻委員會的史蒂文·霍金斯説,他認為該法案不太可能在參議院獲得通過。美國大麻委員會是一個倡導大麻合法化的組織。

"At the moment we're certainly supportive of these broader efforts, but I'm not sure the votes are there," said Mr. Hawkins, president and CEO of USCC.

“目前我們當然支持這些更廣泛的努力,但我不確定投票結果是否存在,”USCC總裁兼首席執行官霍金斯説。

Senate Majority Leader Chuck Schumer (D., N.Y.) said in a statement Friday he hopes to introduce legislation to the floor soon.

參議院多數黨領袖查克·舒默(紐約州民主黨人)他在週五的一份聲明中説,他希望儘快向議會提交立法。

"Of course, we will need Republicans to pass a legalization bill in the Senate, and we will be working hard to try and get them," Mr. Schumer said.

“當然,我們需要共和黨人在參議院通過一項合法化法案,我們將努力爭取他們,”舒默説。

This isn't the first time the House has passed legislation to decriminalize marijuana at the federal level. In December 2020, the chamber voted 228-164 to pass the MORE Act of 2020. But that bill didn't make it far among senators before they adjourned the following month.

這並不是眾議院第一次通過立法,在聯邦一級將大麻合法化。2020年12月,眾議院以228票對164票通過了2020年的More法案。但這項法案在參議員們下個月休會之前並沒有得到太多參議員的支持。

Toi Hutchinson of the Marijuana Policy Project, a national organization advocating for the legalization of marijuana, said the House repeatedly passing the bill shows the movement is gaining momentum.

大麻政策項目是一個倡導大麻合法化的全國性組織,該組織的託伊·哈欽森表示,眾議院一再通過該法案,表明這場運動的勢頭正在增強。

"While this is historic in nature and warrants praise, it is necessary to also recognize that the fight is still far from over," Ms. Hutchinson said.

“雖然這是歷史性的,值得稱讚,但也有必要認識到,這場鬥爭還遠未結束,”哈欽森説。

Write to Camille Furst at camille.furst@wsj.com

寫信給Camille Furst:camille.Furst@wsj.com

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論